Tmu­ni­ty teams up with On­co­ra Med­ical; T3D re­ceives ad­di­tion­al fund­ing for Alzheimer's study

→ Us­man “Oz” Azam–led Tmu­ni­ty Ther­a­peu­tics — which re­cent­ly bagged $75 mil­lion, bring­ing their to­tal to-date fund­ing to $231 mil­lion — has en­tered in­to a col­lab­o­ra­tion with On­co­ra Med­ical to ac­cess On­co­ra’s re­al-world da­ta plat­form to sup­port the de­sign of fu­ture clin­i­cal cell ther­a­py pro­grams.

→ Af­ter re­ceiv­ing a $9 mil­lion grant from the NIA to help fund a Phase II clin­i­cal study of the com­pa­ny’s meta­bol­ic-fo­cused Alzheimer’s treat­ment in May, T3D Ther­a­peu­tics has closed a $15 mil­lion fi­nanc­ing round from a cor­ner­stone in­vestor. The com­pa­ny says that this along with the grant from the NIA com­pletes the fund­ing need­ed to be­gin the PI­O­NEER study of the treat­ment, T3D-959.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER